van Ewijk, Hanneke
Noordermeer, Siri D. S.
Heslenfeld, Dirk J.
Luman, Marjolein
Hartman, Catharina A.
Hoekstra, Pieter J.
Faraone, Stephen V.
Franke, Barbara
Buitelaar, Jan K.
Oosterlaan, J.
Funding for this research was provided by:
National Institutes of Health (R01MH62873)
NWO (1750102007010)
Article History
Received: 22 April 2015
Accepted: 7 October 2015
First Online: 27 October 2015
Compliance with ethical standards
:
: In the past year, Dr. Faraone received income, travel expenses and/or research support from and/or has been on an Advisory Board for Pfizer, Ironshore, Shire, Akili Interactive Labs, CogCubed, Alcobra, VAYA Pharma, Neurovance, Impax, NeuroLifeSciences and research support from the National Institutes of Health (NIH), the K.G. Jebsen Centre for Research on Neuropsychiatric Disorders, University of Bergen, Bergen, Norway and the European Community’s Seventh Framework Programme (FP7/2007-2013) under Grant Agreement No. 602805. With his institution, he has US patent US20130217707 A1 for the use of sodium–hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received consulting fees or was on Advisory Boards or participated in continuing medical education programs sponsored by: Shire, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. Dr. Faraone receives royalties from books published by Guilford Press: <i>Straight Talk about Your Child’s Mental Health</i>, Oxford University Press: <i>Schizophrenia: The Facts</i> and Elsevier, <i>ADHD: Non</i>-<i>Pharmacologic Treatments</i>. Dr. Hoekstra has received a research grant from Shire and has been member of advisory boards of Eli Lilly and Shire. Dr. Buitelaar has been in the past 3 years a consultant to/member of advisory board of/and/or speaker for Janssen Cilag BV, Eli Lilly, Shire, Novartis, Roche and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties. Dr. Oosterlaan has received unrestricted investigator initiated research grants from Shire pharmaceuticals. Dr. Franke received a speaker fee from Merck. Dr. Heslenfeld, Dr. Luman, Dr. Hartman, and Ms. Noordermeer and Dr. van Ewijk report no conflicts of interest.